Lista de obras -

A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster

artículo científico publicado en 2003

ALK and NSCLC: Targeted therapy with ALK inhibitors ⬇️

artículo científico publicado el 1 de enero de 2011

ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation

artículo científico publicado en 2021

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684 ⬇️

artículo científico publicado el 15 de diciembre de 2011

Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines

artículo científico publicado en 2004

Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.

artículo científico publicado en 2016

Anaplastic lymphoma kinase: signalling in development and disease

artículo científico publicado en 2009

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy

artículo científico publicado en 2010

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice

artículo científico publicado en 2016

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

artículo científico publicado en 2012

Characterization of the expression of the ALK receptor tyrosine kinase in mice

artículo científico publicado en 2006

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

scientific article published on 01 August 2018

Crizotinib--latest champion in the cancer wars? ⬇️

artículo científico publicado el 28 de octubre de 2010

Delineation of exoenzyme S residues that mediate the interaction with 14-3-3 and its biological activity

artículo científico publicado en 2006

Electrostatic interactions play a minor role in the binding of ExoS to 14-3-3 proteins

artículo científico publicado en 2010

Exoenzyme S of Pseudomonas aeruginosa is not able to induce apoptosis when cells express activated proteins, such as Ras or protein kinase B/Akt

artículo científico publicado en 2006

Exoenzyme S shows selective ADP-ribosylation and GTPase-activating protein (GAP) activities towards small GTPases in vivo

artículo científico publicado en 2002

Goliath family E3 ligases regulate the recycling endosome pathway via VAMP3 ubiquitylation.

artículo científico publicado en 2013

Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation.

artículo científico publicado en 2006

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

artículo científico publicado en 2014

Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion.

artículo científico publicado en 2003

Jeb/Alk signalling regulates the Lame duck GLI family transcription factor in the Drosophila visceral mesoderm.

artículo científico publicado en 2013

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas

artículo científico publicado en 2017

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

artículo científico publicado en 2013

Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation

artículo científico publicado en 2017

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways

article

Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.

artículo científico publicado en 2013

Phosphorylation-independent interaction between 14-3-3 and exoenzyme S: from structure to pathogenesis

artículo científico publicado en 2007

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells

scientific article published on 18 December 2019

Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism

artículo científico publicado en 2015

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

artículo científico publicado en 2016

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

artículo científico publicado en 2020

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma

artículo científico publicado en 2014

The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK.

artículo científico publicado en 2007

Lista de obras de

A crucial role for the Anaplastic lymphoma kinase receptor tyrosine kinase in gut development in Drosophila melanogaster

ALK and NSCLC: Targeted therapy with ALK inhibitors ⬇️

ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684 ⬇️

Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines

Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.

Anaplastic lymphoma kinase: signalling in development and disease

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

Characterization of the expression of the ALK receptor tyrosine kinase in mice

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

Crizotinib--latest champion in the cancer wars? ⬇️

Delineation of exoenzyme S residues that mediate the interaction with 14-3-3 and its biological activity

Electrostatic interactions play a minor role in the binding of ExoS to 14-3-3 proteins

Exoenzyme S of Pseudomonas aeruginosa is not able to induce apoptosis when cells express activated proteins, such as Ras or protein kinase B/Akt

Exoenzyme S shows selective ADP-ribosylation and GTPase-activating protein (GAP) activities towards small GTPases in vivo

Goliath family E3 ligases regulate the recycling endosome pathway via VAMP3 ubiquitylation.

Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation.

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion.

Jeb/Alk signalling regulates the Lame duck GLI family transcription factor in the Drosophila visceral mesoderm.

MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma Mutation

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways

Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.

Phosphorylation-independent interaction between 14-3-3 and exoenzyme S: from structure to pathogenesis

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells

Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma

The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK.